Ownership and insider activity for CNS Pharmaceuticals, Inc. (CNSP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
Price
| Price | $5.50 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-18 | Fisher Michal | P-Purchase | 2,000 | $10K |
| 2026-05-04 | Fisher Michal | |||
| 2026-08-14 | Levin Rami | M-Exempt | 4,750 | |
| 2026-08-14 | Levin Rami | M-Exempt | 4,750 | |
| 2026-05-18 | Charles Faith L. | P-Purchase | 7,100 | $34K |
| 2026-03-02 | Faulkner Eric | A-Award | 9,500 | |
| 2026-03-02 | Faulkner Eric | |||
| 2026-03-02 | O'Loughlin Steve | A-Award | 9,500 | |
| 2026-03-02 | O'Loughlin Steve | |||
| 2026-01-01 | Levin Rami | A-Award | 19,000 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110543 | $282736 | $7.2M | $14.0M | $5.0M | $10.1M | $548721 | $6.5M | $7.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $882539 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $162194 | $588133 | $7.9M | $15.5M | $7.5M | $12.6M | $1.6M | $8.7M | $8.1M |
| Property, Plant & Equipment | 0 | 0 | $18165 | $23431 | $16109 | $5664 | $4933 | $6005 | $17703 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $162194 | $683333 | $7.9M | $15.9M | $8.8M | $13.1M | $1.7M | $8.7M | $8.6M |
| Accounts Payable | $57497 | $128865 | $289499 | $946330 | $1.5M | $3.7M | $5.8M | $2.2M | $3.8M |
| Short-term Debt | $121825 | $316918 | 0 | $439294 | $387794 | $409968 | $300806 | $326072 | $328571 |
| Total Current Liabilities | $220726 | $1.2M | $311000 | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $220726 | $1.2M | $311000 | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Retained Earnings | -$219362 | -$7.6M | -$11.5M | -$20.9M | -$35.0M | -$50.7M | -$69.6M | -$84.4M | -$100.3M |
| Total Equity | -$58532 | -$549298 | $7.6M | $13.9M | $6.6M | $8.1M | -$4.4M | $6.2M | $4.5M |
| Total Debt | $121825 | $316918 | 0 | $439294 | $387794 | $409968 | $300806 | $326072 | $328571 |
| Net Debt | $11282 | $34182 | -$7.2M | -$13.6M | -$4.6M | -$9.6M | -$247915 | -$6.1M | -$6.9M |
| Working Capital | -$58532 | -$644498 | $7.6M | $13.6M | $5.3M | $7.6M | -$4.5M | $6.1M | $4.0M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.86 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -21.50 |
Profitability
| Return on Equity | -204.25% |
| Return on Invested Capital | -92.94% |
| Return on Assets | -76.12% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CMND · ENSC · GRI · KTTA · NLSP · OGEN · SILO
Explore sector: Healthcare · Biotechnology
More sections of CNSP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks